Brokers Set Expectations for ODTX Q3 Earnings

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) – Research analysts at HC Wainwright issued their Q3 2026 EPS estimates for shares of Odyssey Therapeutics in a research report issued on Thursday, August 27th. HC Wainwright analyst E. Bodnar expects that the company will post earnings per share of ($1.13) for the quarter. HC Wainwright has a “Buy” rating and a $44.00 price target on the stock. The consensus estimate for Odyssey Therapeutics’ current full-year earnings is ($5.99) per share. HC Wainwright also issued estimates for Odyssey Therapeutics’ Q4 2026 earnings at ($1.19) EPS, FY2026 earnings at ($6.13) EPS, FY2027 earnings at ($5.18) EPS, FY2028 earnings at ($4.93) EPS, FY2029 earnings at ($4.68) EPS and FY2030 earnings at ($4.15) EPS.

Several other research analysts have also recently issued reports on the stock. Wall Street Zen cut shares of Odyssey Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 20th. Zacks Research upgraded Odyssey Therapeutics to a “hold” rating in a research report on Wednesday, June 3rd. Weiss Ratings assumed coverage on Odyssey Therapeutics in a research note on Tuesday, August 11th. They set a “sell (d+)” rating for the company. Wedbush began coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $30.00 target price for the company. Finally, Oppenheimer reissued an “outperform” rating and issued a $40.00 price target on shares of Odyssey Therapeutics in a report on Thursday, June 18th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $35.75.

Odyssey Therapeutics Trading Up 0.7%

Shares of NASDAQ:ODTX opened at $24.52 on Monday. Odyssey Therapeutics has a fifty-two week low of $15.10 and a fifty-two week high of $28.00. The company has a 50-day moving average price of $19.80. The stock has a market capitalization of $1.18 billion and a P/E ratio of -3.62.

Odyssey Therapeutics (NASDAQ:ODTX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.74) EPS for the quarter.

About Odyssey Therapeutics

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc is based in BOSTON.